MedTrace Logo

Evaluate the Efficacy and Safety of GZR101-80 Injection in Patients With Type 2 Diabetes

NCT07387003 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 345

Last updated 2026-04-15

No results posted yet for this study

Summary

This study will be conducted to evaluate the efficacy and safety of GZR101-80 Injection in patients with type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs or Basal Insulin.

Conditions

  • Type 2 Diabetes (T2DM)

Interventions

DRUG

GZR101-80

Administered SC

DRUG

GZR33 or Insulin degludec/Insulin aspart or Insulin aspart30 (NovoRapid®30)

Administered SC

Sponsors & Collaborators

  • Gan & Lee Pharmaceuticals.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-10
Primary Completion
2027-02-11
Completion
2027-09-23

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07387003 on ClinicalTrials.gov